Deadline: 06/20/23 23:59 Eastern Standard Time (e.g., New York, GMT -5)
Save
Add to calendar
Grant Description
Grants of up to $80,000 to USA institutions of higher education for fellowship programs for cardiologists. Funding may be used for benefits that support the fellow and salary. The fellowship is intended for individuals with a strong focus on practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grants will be available for both established and emerging Transthyretin Cardiac Amyloidosis Fellowship programs.
- Accredited, US-based academic institution.
- Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual.
- Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training may be included in the program but is not required.
- Examples of independent research include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health.
- Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions.
- Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.
Requirements for Prospective Fellows:
- Institution must ensure that any fellow that will receive grant funds must be a U.S. Worker (U.S. citizen, permanent resident, refugee, or asylee), or hold an appropriate non-immigrant visa status authorizing employment in the U.S.
- U.S. Physician Payments Sunshine Act (“Sunshine Act”) and other transparency law requirements must be satisfied with respect to meals, payments and other transfers of value. As a condition of the grant, the selected fellow will be named in transparency reporting as a recipient of grant funding.
Ineligible
No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.
Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.).
Grant funds cannot be used for overhead or indirect costs.
No aspect of the fellowship program budget can reflect a benefit to Pfizer’s business or a Pfizer asset.
Pre-Application Information
Timeline:
- RFP Release Date: 3/29/2023
- Full Proposal Due Date: 6/20/2023
- Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Review of Full Proposals by ERP: August 2023
- Anticipated Full Proposal Notification Date: September 2023
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: July 2024 to June 2025
Funding will be awarded to the institution, not an individual.
All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review period.
Number of Grants
Pfizer anticipates awarding 2 grants.
Estimated Size of Grant
Grant funding is available to support one fellow for up to a year at $80,000.
Term of Contract
Anticipated Project Start and End Dates: July 2024 to June 2025
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com), with the subject line “US Cardiac Amyloidosis Fellowship.”
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
We use cookies to enhance your browsing experience on GrantWatch.com. By continuing to use our site, you consent to the use of cookies. Learn more by exploring our comprehensive Cookie Policy
